Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Where do we go from here ?

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 04, 2021 11:28am

106 Views

Post# 32715137

RE:RE:Where do we go from here ?

Yes Year 3000 that is the point I am making. We will not attract any major investors until we get some further information on the roll out of the Dermal Injector. Without major investors we will not see any significant rise in the share price.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism